Cheng Y, Sun YS, He YM. ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model. World J Gastrointest Oncol 2026; 18(7): 118940 [DOI: 10.4251/wjgo.v18.i7.118940]
Corresponding Author of This Article
Yun Cheng, Research Fellow, Department of Integrated Traditional Chinese Medicine and Western, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, No. 42 Baiziting, Nanjing 210009, Jiangsu Province, China. chengyun_nj@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
research-article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cheng Y, Sun YS, He YM. ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model. World J Gastrointest Oncol 2026; 18(7): 118940 [DOI: 10.4251/wjgo.v18.i7.118940]
World J Gastrointest Oncol. Jul 15, 2026; 18(7): 118940 Published online Jul 15, 2026. doi: 10.4251/wjgo.v18.i7.118940
ST2, PIVKA-II, CEA, CA125 and their combinations in elderly liver metastases cancers: Development of a diagnostic scoring model
Yun Cheng, Yan-Sha Sun, Yong-Ming He
Yun Cheng, Yong-Ming He, Department of Integrated Traditional Chinese Medicine and Western, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China
Yan-Sha Sun, Department of Oncology, Huai’an Hospital of Huai’an City, Huai’an 223200, Jiangsu Province, China
Author contributions: Cheng Y was responsible for research design, funding application, data analysis, review and editing, communication and coordination, ethical review, copyright and licensing, and follow-up; Sun YS, He YM were responsible for data analysis and paper writing; He YM participated in research design; and all authors have read and approved the final manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, approval No. KY-2025-028.
Informed consent statement: All research participants or their legal guardians provided written informed consent prior to study registration.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No other data available.
Corresponding author: Yun Cheng, Research Fellow, Department of Integrated Traditional Chinese Medicine and Western, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, No. 42 Baiziting, Nanjing 210009, Jiangsu Province, China. chengyun_nj@163.com
Received: January 30, 2026 Revised: February 12, 2026 Accepted: April 1, 2026 Published online: July 15, 2026 Processing time: 156 Days and 12.3 Hours
Core Tip
Core Tip: Based on the logistic regression analysis, a risk scoring model incorporating soluble growth-stimulating gene 2, protein induced by vitamin K absence or antagonist-II, carcinoembryonic antigen, carbohydrate antigen 125, and fatty liver history was developed to predict liver metastasis in elderly colorectal and lung cancer patients. The soluble growth-stimulating gene 2 + protein induced by vitamin K absence or antagonist-II + carcinoembryonic antigen + carbohydrate antigen 125 combination achieved the optimal diagnostic balance (area under the curve = 0.896), with specificity reaching 98.42%. Risk stratification significantly correlated with metastasis incidence (93.2% in high-risk vs 10.4% in low-risk). This quantitative model provides a simple, non-invasive tool for early identification of high-risk patients, facilitating personalized surveillance and timely intervention.
